©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
A Key Role for Protein Kinase A in Homologous Desensitization of the -Adrenergic Receptor Pathway in S49 Lymphoma Cells (*)

(Received for publication, September 15, 1995; and in revised form, November 8, 1995)

Steven R. Post Olga Aguila-Buhain Paul A. Insel (§)

From the Department of Pharmacology, University of California, San Diego, La Jolla, California 92093-0636

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

We have used a [^3H]forskolin binding assay to assess G(s)-adenylyl cyclase interactions in intact wild-type (WT) and kin S49 cells under conditions that desensitize the beta(2)-adrenergic receptor (beta(2)-AR) system. This assay provides a measurement of Galpha(s)-adenylyl cyclase interaction that does not rely on the determination of second messenger accumulation or enzyme activity in broken cells. Kin S49 cells lack protein kinase A (PKA) activity and provide a unique system in which to study the relative importance of this enzyme in beta(2)-AR desensitization. Although both WT and kin S49 cells display similar kinetics of cAMP accumulation and agonist-induced cell-surface beta(2)-AR loss, we found that these cell types exhibited very different extents of desensitization of forskolin binding following agonist treatment. Specifically, 10 µM isoproterenol (37 °C, 30 min) induced the loss of 70% of [^3H]forskolin binding sites in WT cells but only 30% in kin cells. This loss of sites in WT cells displayed a t of approx7 min, was agonist concentration-dependent (EC approx 60 nM), was not mimicked by 8-Br-cAMP, and could be blocked by the PKA inhibitor, H89. The difference between WT and kin cells in agonist-induced desensitization of the beta(2)-AR pathway was also noted in studies of cAMP accumulation in cells. In addition, preincubation of intact cells with isoproterenol did not inhibit guanine nucleotide-dependent [^3H]forskolin binding in permeabilized cells. Overall, data obtained from [^3H]forskolin binding assays demonstrate the involvement of PKA in the agonist-dependent uncoupling of beta(2)-AR and G(s); thus we conclude that PKA plays an important role in the homologous desensitization of the beta(2)-AR-G(s)-adenylyl cyclase pathway in intact cells.


INTRODUCTION

Desensitization of receptor-mediated cellular responses is a complex process which can involve multiple pathways including: (a) receptor uncoupling from G protein, (b) sequestration of receptors away from the plasma membrane, and (c) down-regulation of signaling proteins(1, 2, 3, 4) . It has been demonstrated that uncoupling of receptor and G protein occurs rapidly (within 10 min) in response to receptor activation and appears to involve receptor phosphorylation(5) . In the case of the beta(2)-adrenergic receptor (beta(2)-AR) (^1)system, agonist-occupied receptors activate the stimulatory G protein, G(s), which in turn promotes the production of cAMP by adenylyl cyclase. Increased cAMP levels activate the cAMP-dependent protein kinase (PKA) resulting in the phosphorylation of several proteins, including the beta(2)-AR and other receptors. In addition, agonist-occupied beta(2)-AR are phosphorylated by one or more isoforms of the beta-adrenergic receptor kinase (beta-ARK, also termed G protein receptor kinase; GRK) resulting in the uncoupling of receptor and G(s)(6, 7, 8, 9, 10) . Therefore, both PKA and beta-ARK can contribute to desensitization of the beta(2)-AR system.

In contrast to the effect of beta-ARK, PKA-mediated beta(2)-AR phosphorylation is most often associated with heterologous desensitization (that which is agonist nonspecific and therefore not dependent on beta(2)-AR occupancy), but is generally thought to be of little importance in homologous desensitization (agonist-specific and dependent on beta(2)-AR occupancy)(11, 12, 13, 14) . Therefore, while the beta(2)-AR can be phosphorylated by both PKA and beta-ARK, most recent work has focused on the importance of beta-ARK and related proteins (reviewed in (6) and (15) -17) as mediators of homologous desensitization.

The kin S49 murine lymphoma cell lacks PKA activity and thus provides a unique system in which to study the relative importance of PKA in mediating various cellular responses. Importantly, both WT and kin S49 cells express only the beta(2)-AR isoform and display similar profiles of beta-AR agonist-induced desensitization of cAMP production and cell-surface beta(2)-AR loss(14, 18) . The ability of the cell-permeable cAMP analog, 8-Br-cAMP, to mimic the effect of epinephrine in decreasing beta-AR agonist-induced adenylyl cyclase activity in membranes prepared from treated cells suggest that the effect of PKA activation is not dependent on the presence of agonist(11) . These results suggest that PKA is not involved in homologous desensitization of the beta(2)-AR.

In the current studies, we have used a [^3H]forskolin binding assay to define more precisely the role of PKA in desensitizing the beta(2)-AR system in intact S49 cells. Since high-affinity forskolin interaction with adenylyl cyclase requires the activation of Galpha(s), the amount of [^3H]forskolin associated with cells can be used as an index of Galpha(s)-adenylyl cyclase interaction(19, 20, 21) . This assay, therefore, both provides a direct means of assessing hormone-stimulated Galpha(s)-adenylyl cyclase interaction in intact cells that is independent of second messenger accumulation and maintains components of the intracellular milieu important for regulating adenylyl cyclase activity and that may be altered in membrane preparations. Using forskolin binding assays, we compared Galpha(s)-adenylyl cyclase interactions in WT and kin S49 cells under conditions that desensitize the beta(2)-AR system. We reasoned that a decrease in the beta(2)-AR-stimulated [^3H]forskolin binding would reflect the functional desensitization of the beta(2)-AR pathway and that a difference in the extent of desensitization between WT and kin cells would demonstrate the importance of PKA in this process. Using this [^3H]forskolin binding assay, we found that, in contrast to previous studies(11, 12, 13, 14) , PKA plays an important role in homologous desensitization of the beta(2)-AR.


EXPERIMENTAL PROCEDURES

Cell Culture and Permeabilization

Wild-type S49 lymphoma cells and kin S49 clonal variants were used in these studies, the kin variant lacks cAMP-dependent protein kinase activity(22, 23) . All cells were grown at 37 °C in Dulbecco's modified Eagle's medium containing 10% horse serum as described previously(24) . Cells were maintained in logarithmic growth conditions (0.3-1.2 times 10^6 cells/ml). Cell number and viability were determined using a Coulter ZBI cell counter/Channelizer. Prior to permeabilization, cells (1 times 10^6/ml) were centrifuged (200 times g, 5 min, 4 °C) and suspended at 2 times 10^6/ml in a ``reverse'' buffer (100 mM KCl, 20 mM NaCl, 1 mM NaH(2)PO(4), 20 mM HEPES, 1 mM MgSO(4), pH 7.4). Saponin (10 mg/ml in Me(2)SO) was added to the cell suspension at a final concentration of 30 µg/ml and cells incubated at 37 °C for 10 min. The cells were then centrifuged and suspended in reverse buffer. Using these conditions, geq97% of cells were permeabilized as assessed by uptake of trypan blue.

[H]Forskolin Binding

[^3H]Forskolin binding was determined as described previously(19, 21) . Briefly, intact S49 cells were incubated in Dulbecco's modified Eagle's medium buffered with 20 mM HEPES, pH 7.4 (DMEH) and permeabilized cells were incubated in reverse buffer. Following pretreatment (as indicated in figure legends), cells (5 times 10^6) were incubated with 40 nM [^3H]forskolin in the absence (total binding) or presence (nonspecific binding) of 10 µM unlabeled forskolin at 25 °C for 10 min. The cells were rapidly filtered over Whatman GF/C filters with 5 ml of ice-cold wash buffer (50 mM Tris-HCl, 10 mM MgCl(2), pH 7.4) and washed with an additional 20 ml of cold buffer. [^3H]Forskolin remaining associated with cells was determined by scintillation counting of the filters.

cAMP Assays

Cells (1 times 10^6) were incubated in the presence or absence of isoproterenol (1 µM) or forskolin (1 µM) for 30 min at 37 °C. Following this treatment, isobutylmethylxanthine (200 µM, final concentration, to inhibit phosphodiesterase activity) together with either buffer, isoproterenol (1 µM) or forskolin (1 µM), were added and incubations continued for an additional 7 min. Reactions were terminated by the addition of trichloroacetic acid (7.5% w/v final). The amount of cAMP in samples was quantitated by radioimmunoassay following the acetylation of aliquots according to manufacturer's protocol (Calbiochem, La Jolla, CA).

Materials

Reagents were purchased from the following sources: [^3H]forskolin from NEN DuPont; forskolin and anti-cAMP antibody were from Calbiochem; saponin, isoproterenol, 8-Br-cAMP, and isobutylmethylxanthine were from Sigma.


RESULTS

In response to isoproterenol, WT and kin S49 cells display a similar amount of [^3H]forskolin binding (19, and data not shown). This increase is dependent upon beta-AR-mediated activation of the stimulatory G protein, Galpha(s)(19, 25) . However, following the preincubation of cells with isoproterenol (10 µM) for various times (5-60 min), WT and kin cells differ in the extent to which the agonist promotes an increase in forskolin binding sites (Fig. 1). Specifically, whereas only 28 ± 3% of control isoproterenol-stimulated [^3H]forskolin binding remained following a 60-min preincubation of WT S49 cells with agonist, kin S49 cells retained 64 ± 7% of these sites (p < 0.05 versus WT). In each case, the extent of desensitization of forskolin binding reached maximum by about 30 min of incubation with agonist and displayed a t approx 7 min. When WT cells were treated with the PKA inhibitor H89 (3 µM) the extent of isoproterenol-induced desensitization of [^3H]forskolin binding was similar to that observed for kin cells (Table 1). Importantly, this concentration of H89 had no effect either on the activity of recombinant GRK(2) (beta-ARK(1), data not shown) or on the extent of desensitization observed in kin cells (data not shown).


Figure 1: Desensitization of isoproterenol-stimulated forskolin binding in WT and kin S49 cells. WT and kin S49 cells were preincubated with 10 µM isoproterenol for the indicated times. Following pretreatment, 40 nM [^3H]forskolin was added, the incubation was continued for an additional 10 min, and radioactivity associated with cells was determined as described under ``Experimental Procedures.'' Radioactivity associated with cells in the absence of isoproterenol (i.e. non-stimulated binding; WT = 1679 ± 116, kin = 1627 ± 197 sites per cell) was subtracted and the data normalized to the amount of isoproterenol-stimulated [^3H]forskolin bound to cells preincubated in buffer alone (WT = 1241 ± 143; kin = 1599 ± 229 sites per cell). The average ± S.E. of three separate experiments performed in triplicate is shown. The curve represents a mathematical fit of the data to a one-phase exponential decay equation.





Since PKA activation is dependent on cAMP production, we compared the concentration dependence for isoproterenol-induced desensitization of forskolin binding with that previously described for isoproterenol-stimulated cAMP production(25, 26) . Importantly, the ability of isoproterenol to induce desensitization of [^3H]forskolin binding (EC = 56.5 ± 2.1 nM) parallels its ability to stimulate cAMP production (cf. Fig. 2and (25) and (26) ). Together with data presented in Fig. 1, these results indicate that the different extents of isoproterenol-induced desensitization of [^3H]forskolin binding observed in WT and kin cells results from cAMP-dependent activation of PKA. Furthermore, PKA activity is responsible for about 50% ((% desensitization in WT - % desensitization in kin)/% desensitization in WT times 100%; Fig. 1) of the total desensitization of [^3H]forskolin binding observed in intact WT S49 cells; the desensitization occurring in kin cells is presumably due to the activity of beta-ARK and related proteins (5) .


Figure 2: Desensitization of forskolin binding in WT S49 cells depends on agonist concentration. WT S49 cells were preincubated for 60 min at 25 °C with the indicated concentration of isoproterenol. Following pretreatment, 40 nM [^3H]forskolin was added together with 10 µM isoproterenol and the incubation was continued for 10 min and processed as described under ``Experimental Procedures.'' Points were determined in triplicate and radioactivity associated with cells in the presence of 10 µM forskolin (nonspecific; 232 ± 102 cpm, 928 ± 394 sites per cell) subtracted. The curve represents a mathematical fit of the data to a sigmoidal curve. Similar results were obtained in two separate experiments.



To determine if results from isoproterenol-induced desensitization of [^3H]forskolin binding assays correlate with an effect on second messenger production, we compared cAMP accumulation in WT and kin cells preincubated with either isoproterenol or forskolin (Fig. 3). Following 30 min of treatment with isoproterenol (1 µM), WT cells displayed a much greater decrease in cAMP production following the addition of forskolin (1 µM) compared to kin cells (40 versus 70% of control cAMP production remaining for WT and kin, respectively; p = 0.03). Treatment of cells with forskolin (1 µM) did not inhibit cAMP production following the addition of isoproterenol (1 µM), indicating that the desensitization of cAMP accumulation depends on the presence of isoproterenol in the preincubation. These results are consistent with results obtained from [^3H]forskolin binding assays in that WT cells display a greater extent of agonist-dependent desensitization relative to kin cells. Thus, we conclude that beta(2)-AR-induced desensitization of both forskolin binding and cAMP production is dependent on the activity of PKA.


Figure 3: Effect of isoproterenol and forskolin treatment on subsequent cAMP accumulation in WT and kin S49 cells. WT and kin S49 cells were preincubated in the presence or absence of isoproterenol (iso) (1 µM) or forskolin (Fsk) (1 µM) for 30 min at 37 °C. Subsequently, isobutylmethylxanthine (200 µM final concentration) and either isoproterenol (1 µM) or forskolin (1 µM) were added to cells preincubated with isoproterenol or forskolin, respectively. Incubations continued for an additional 7 min at 37 °C and reactions were terminated by the addition of trichloroacetic acid (7.5% w/v final concentration). The amount of cAMP present in samples was quantitated by radioimmunoassay as described under ``Experimental Procedures.'' Control (100%) represents cAMP produced following the addition of isobutylmethylxanthine and both isoproterenol and forskolin to cells preincubated in buffer (dotted line, absolute amount of cAMP varied between experiments but typically ranged between 200-400 pmol per 10^6 WT cells and 400-600 pmol per 10^6 kin cells). Shown are the mean ± S.E. of three individual experiments performed in triplicate.



While the above data demonstrate the importance of PKA in beta(2)-AR-induced desensitization of Galpha(s)-adenylyl cyclase interaction, they do not indicate the site(s) or mechanism (heterologous versus homologous) by which this effect occurs. The beta(2)-AR contains two consensus PKA phosphorylation sequences and thus could represent one site for PKA-mediated desensitization(27) . In addition, it has been suggested that certain isoforms of adenylyl cyclase are subject to direct regulation by PKA(28) . This is particularly important in that one such isoform, Type VI, is expressed in S49 cells(29) . To test whether PKA-mediated desensitization of the beta(2)-AR pathway in WT S49 cells occurs via homologous or heterologous pathways, we tested (a) the ability of guanine nucleotide to stimulate [^3H]forskolin binding in permeabilized cells following isoproterenol pretreatment, and (b) the ability of agents that increase cAMP, and hence activate PKA, to mimic the effect of isoproterenol preincubation on [^3H]forskolin binding in intact WT cells.

To determine if the effect of isoproterenol preincubation on subsequent [^3H]forskolin binding results from alterations in the ability of Galpha(s) to bind guanine nucleotides or interact with adenylyl cyclase, we examined GTPS-stimulated [^3H]forskolin binding in saponin-permeabilized WT S49 cells. As shown in Fig. 4, isoproterenol (10 µM) did not increase [^3H]forskolin binding in permeabilized cells. However, [^3H]forskolin binding in permeabilized cells was increased by the addition of GTPS (30 µM) either alone or with isoproterenol. While isoproterenol did not affect the total amount of [^3H]forskolin bound in the presence of GTPS, the agonist decreased the time required to achieve the full extent of forskolin binding (data not shown). The amount of guanine nucleotide-stimulated [^3H]forskolin binding in permeabilized cells was similar to that observed in intact cells incubated in the presence of isoproterenol. Incubation of cells with isoproterenol (10 µM, 60 min) prior to permeabilization did not affect the amount of [^3H]forskolin bound in the presence of GTPS following permeabilization. Since isoproterenol affected the rate of [^3H]forskolin binding to permeabilized cells, the concentration of isoproterenol (10 µM) used in the preincubation of intact cells was maintained throughout permeabilization and subsequent incubation with [^3H]forskolin in order to avoid dissociation of the beta-AR agonist from receptor. These results indicate that the ability of Galpha(s) to bind guanine nucleotide and to interact with adenylyl cyclase is not impaired by isoproterenol preincubation. Therefore, PKA-mediated desensitization of [^3H]forskolin binding observed in WT cells appears not to result from PKA-mediated effect on Galpha(s) or adenylyl cyclase but rather from a functional uncoupling of the beta(2)-AR and G(s).


Figure 4: Isoproterenol treatment of intact cells does not affect guanine nucleotide-dependent forskolin binding following cell permeabilization. Intact WT S49 cells were incubated with or without 10 µM isoproterenol and 40 nM [^3H]forskolin for 10 min as described under ``Experimental Procedures'' (left bars). Saponin-permeabilized cells were incubated with [^3H]forskolin (40 nM) and either 10 µM isoproterenol, 30 µM GTPS, or both as described under ``Experimental Procedures'' (middle bars). To examine the effect of isoproterenol-induced desensitization on guanine nucleotide-dependent [^3H]forskolin binding in permeabilized cells, intact WT cells were preincubated in DMEH with buffer or 10 µM isoproterenol for 60 min at 25 °C. The cells were then permeabilized in reverse buffer containing 10 µM isoproterenol, washed, and incubated in reverse buffer containing 40 nM [^3H]forskolin, 10 µM isoproterenol, and 30 µM GTPS for 10 min (right bars). Radioactivity associated with cells in the presence of 10 µM forskolin was subtracted from each point. Data represent the mean ± S.E. of at least three separate experiments.



Since PKA-mediated phosphorylation of receptors has been associated with heterologous desensitization(11, 12, 13, 14) , we reasoned that increasing intracellular cAMP levels (thereby activating PKA) with cell-permeable cAMP analogs and phosphodiesterase inhibitors should mimic the effect of isoproterenol preincubation on [^3H]forskolin binding. As shown in Table 1, preincubation of WT S49 cells with 8-Br-cAMP (1 mM) and phosphodiesterase inhibitors (isobutylmethylxanthine (100 µM) + RO201724 (100 µM)) for 60 min did not alter the amount of [^3H]forskolin bound following the addition of isoproterenol. These results agree with those obtained from cAMP assays showing that preincubation of WT cells with forskolin does not induce desensitization of the beta(2)-AR response (see Fig. 3). Heterologous desensitization of beta(2)-AR-stimulated [^3H]forskolin binding and cAMP production following treatment with agents which increase intracellular cAMP levels was not observed under these conditions. Heterologous desensitization in intact cells is often manifest by an increase in the concentration of hormone required to elicit a response without changes in the maximal effect of the agonist(11) . For this reason, the conditions used in these experiments examining maximal beta-AR-stimulated Galpha(s)-AC interaction and cAMP production presumably would not detect heterologous desensitization. Overall, we conclude that increasing cAMP does not mimic the isoproterenol-induced desensitization of the beta(2)-AR system in WT S49 cells, suggesting that PKA is involved in agonist-dependent (i.e. homologous) beta(2)-AR desensitization.

To examine further the role of PKA in homologous receptor desensitization, we compared the ability of prostaglandin E(1), another receptor agonist that increases cAMP in S49 cells, with the ability of isoproterenol to stimulate [^3H]forskolin binding in cells pretreated with either prostaglandin E(1) or isoproterenol. As shown in Fig. 5, isoproterenol-stimulated [^3H]forskolin binding was inhibited by about 70% following pretreatment of cells with isoproterenol (10 µM, 60 min; *, p < 0.05 versus control). Similarly, preincubation of cells with PGE(1) (30 µM, 60 min) inhibited subsequent PGE(1)-stimulated [^3H]forskolin binding by approx75% (*, p < 0.05 versus control). In contrast, isoproterenol stimulation of [^3H]forskolin binding was only slightly (leq25%; p > 0.05) inhibited by pretreatment of cells with PGE(1). Thus, the desensitization of [^3H]forskolin binding following either isoproterenol or PGE(1) pretreatment is specific for the beta(2)-AR and prostaglandin receptor, respectively. Together with data presented above, our results demonstrate that in WT S49 cells PKA serves an important role in homologous receptor desensitization.


Figure 5: Homologous desensitization of PGE(1) and isoproterenol-stimulated forskolin binding in WT S49 cells. Intact WT S49 cells were preincubated in DMEH with or without PGE(1) (30 µM) or isoproterenol (iso) (10 µM) for 30 min at 25 °C (first incubation). Subsequently, [^3H]forskolin (40 nM) and either buffer, PGE(1) or isoproterenol, were added and incubations continued for 10 min (second incubation). Radioactivity associated with cells in the presence of 10 µM forskolin (i.e. nonspecific binding; buffer preincubated = 2663 ± 164, PGE(1) preincubated = 2800 ± 253, isoproterenol; preincubated = 2792 ± 269 sites per cell) was subtracted from each point. Control (100%) represents the amount of specific [^3H]forskolin bound following the addition of agonist to cells preincubated in buffer (basal = 112 ± 24, PGE(1)-stimulated = 855 ± 180, and isoproterenol-stimulated = 1583 ± 209 sites per cell). Shown is the mean ± S.E. of three separate experiments performed in triplicate.




DISCUSSION

Desensitization of receptor-mediated cellular responses is a complex process that can involve multiple pathways. For the beta(2)-AR, phosphorylation by both PKA and beta-ARK can uncouple receptor and G protein(7, 10, 30, 31) . It has been suggested that the ability of PKA to desensitize the beta(2)-AR seemingly does not depend on receptor occupancy by agonist and therefore mediates heterologous desensitization(7, 11, 13, 32) . In contrast, phosphorylation of beta(2)-AR by beta-ARK depends on receptor occupancy and occurs only in the presence of beta-AR agonists(5, 7, 8, 9) . Thus, in contrast to PKA, beta-ARK-mediated phosphorylation is generally thought to be critical for homologous desensitization of the beta(2)-AR.

We examined activation and subsequent desensitization of the beta(2)-AR-G(s)-adenylyl cyclase system in intact cells using an approach different than previous studies (i.e. adenylyl cyclase enzyme assays in membranes). This is of particular physiological importance since adenylyl cyclase activity is regulated by a complex network of interacting pathways (for review, see (33, 34, 35, 36, 37) ). For example, adenylyl cyclase isoforms present in S49 cells, Type VI and Type VII(29, 38) , are regulated by Ca, PKA, PKC, Galpha(s), and Galpha(i) (28, 38, 39 and references therein). Furthermore, the ability to detect receptor desensitization using adenylyl cyclase assays in membranes is influenced by Mg concentration(31, 40, 41) . Thus, multiple modulators of adenylyl cyclase activity can be affected during the preparation and treatment of membranes.

Assessment of forskolin binding provides a means to examine the role of PKA in beta(2)-AR-mediated desensitization that circumvents the problems associated with determining adenylyl cyclase activity in membranes. The interaction of forskolin with adenylyl cyclase is enhanced by the activation of Galpha(s)(19, 37, 42, 43) . Therefore, the amount of [^3H]forskolin associated with cells following agonist treatment can be used as an index of Galpha(s)-adenylyl cyclase interaction(19, 20, 21) . Using this assay, we show here that WT and kin S49 cells display very different extents of receptor-mediated desensitization. That is, whereas about 70% of isoproterenol-stimulated [^3H]forskolin binding sites desensitize in WT cells, only about 30% undergo desensitization in the absence of PKA (i.e. kin cells or in the presence of a PKA inhibitor). This desensitization is dependent on receptor occupancy, as evidenced by the inability of PGE(1) and other agents that raise cAMP to mimic the effect of isoproterenol. Moreover, treatment of intact WT cells with isoproterenol did not effect the amount of guanine nucleotide-dependent forskolin binding following permeabilization of cells. In agreement with [^3H]forskolin binding results, WT cells exhibited a greater extent of agonist-dependent desensitization of cAMP production than kin cells. Overall, these results argue that PKA is important for homologous (i.e. agonist-specific) desensitization of the beta(2)-AR pathway in WT S49 cells.

Several lines of evidence in both WT and kin S49 cells suggest that PKA-mediated phosphorylation of beta(2)-AR is important for heterologous beta(2)-AR desensitization and that beta-ARK mediates homologous desensitization. For example, membranes prepared from WT cells treated with agents that increase cAMP levels (and hence the activity of PKA) display decreased epinephrine-stimulated adenylyl cyclase activity relative to membranes from untreated cells(11) . Likewise, treatment of WT S49 cell membranes with PKA in vitro inhibited epinephrine-stimulated adenylyl cyclase activity (32) . However, there was no additional effect of PKA treatment on adenylyl cyclase activity in membranes prepared from WT cells previously treated with beta-AR agonist. These results suggest that activation of PKA either by beta-AR agonists or by heterologous pathways has a similar effect on beta(2)-AR desensitization and that this desensitization can occur independent of receptor occupancy. In contrast, treatment of WT or kin cells with isoproterenol reduced to the same extent both receptor affinity for agonist and isoproterenol-stimulated adenylyl cyclase activity in membranes prepared from treated cells(5, 14, 44) . These effects were dependent on the presence of beta-AR agonist. Since beta(2)-AR-stimulated adenylyl cyclase activity was inhibited equally in both WT and kin cells, it was concluded that homologous desensitization was mediated by a receptor-specific kinase and not by PKA. Taken together, these results support the conclusion that PKA and beta-ARK mediate heterologous and homologous beta(2)-AR desensitization respectively.

Previous results, however, have not conclusively demonstrated an important role for PKA in homologous beta(2)-AR desensitization. For example, while Shih and Malbon show that isoproterenol treatment of several cell lines decreased the subsequent cAMP response elicited following agonist rechallenge and that the extent of inhibition was substantially reversed in cells treated with PKA antisense cDNA, the requirement for beta(2)-AR occupancy on this desensitization was not investigated(45) . In other studies, Liggett et al. demonstrated that cells expressing the wild-type beta(2)-AR displayed a rapid decrease in the rate of cAMP accumulation after 2 min of agonist stimulation, whereas the increased rate of cAMP production induced by agonist was prolonged in cells expressing beta(2)-AR mutant constructs lacking consensus sites for PKA phosphorylation. Different studies with beta(2)-AR constructs have suggested that mutation of either the putative PKA or beta-ARK consensus phosphorylation sites can reduce beta-AR agonist-mediated desensitization of adenylyl cyclase activity(47) . In contrast, other studies have shown that deletion of putative PKA phosphorylation sites in the beta(2)-AR inhibited heterologous but not homologous receptor desensitization (13) . These seemingly contradictory observations can be reconciled by noting that these mutated beta(2)-AR receptors contain multiple mutations in different domains of the receptor which could indirectly affect receptor function and desensitization(48) . Moreover, the extent of receptor expression can substantially alter beta-AR desensitization(49) . We believe our data obtained using [^3H]forskolin binding assays are the first to demonstrate a role for PKA in homologous beta(2)-AR desensitization in a native cell.

Overall, the data presented here indicate that assessment of [^3H]forskolin binding provides a useful measure to examine desensitization of beta(2)-AR-induced responses in S49 cells. Results from forskolin binding studies indicate that beta-AR-induced PKA activation promotes an uncoupling of the beta(2)-AR receptor and G(s), thereby reducing the responsiveness of this system. The inability of cAMP analogs and forskolin to mimic this effect and the ability of guanine nucleotide to stimulate [^3H]forskolin binding in permeabilized cells pretreated with isoproterenol further suggest that PKA is important for homologous desensitization of the beta-AR-G(s)-adenylyl cyclase system. Taken together with previous results, our data are consistent with a model whereby the concerted phosphorylation of receptor by both PKA and one or more forms of GRK is important for the homologous desensitization of the beta(2)-AR system observed in intact cells.


FOOTNOTES

*
The work was supported by National Institutes of Health Grants GM40781, HL17682, HL53773, and HL35018 (to P. A. I.) and individual postdoctoral fellowship GM16172 from the National Institutes of Health (to S. R. P). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Dept. of Pharmacology, 0636, University of California at San Diego, La Jolla, CA 92093-0636.

(^1)
The abbreviations used are: beta(2)-AR, beta(2)-adrenergic receptor; WT, wild-type S49 cells; PKA, protein kinase A; beta-ARK, beta-adrenergic receptor kinase; GRK, G protein-coupled receptor kinase; cAMP, 3`,5`-cyclic adenosine monophosphate; PGE(1), prostaglandin E(1); PDE, phosphodiesterase; 8-Br-cAMP, 8-bromo-cAMP; GTPS, guanosine 5`-3-O-(thio)triphosphate.


ACKNOWLEDGEMENTS

We thank Dr. Ginell R. Post for critical reading of this manuscript, Rachel Mastandrea for help in conducting cAMP assays, and Kelly Bell for technical assistance.


REFERENCES

  1. Benovic, J. L., Bouvier, M., Caron, M. G. & Lefkowitz, R. J. (1988) Annu. Rev. Cell Biol. 4, 405-428 [CrossRef]
  2. Hausdorff, W. P., Caron, M. G. & Lefkowitz, R. J. (1990) FASEB J. 4, 2881-2889 [Abstract]
  3. Lefkowitz, R. J., Cotecchia, S., Kjelsberg, M. A., Pitcher, J., Koch, W. J., Inglese, J. & Caron, M. G. (1993) Adv. Second Messenger Phosphoprotein Res. 28, 1-9 [Medline] [Order article via Infotrieve]
  4. Sibley, D. R., Benovic, J. L., Caron, M. G. & Lefkowitz, R. J. (1987) Adv. Exp. Med. Biol. 221, 253-273 [Medline] [Order article via Infotrieve]
  5. Strasser, R. H., Sibley, D. R. & Lefkowitz, R. J. (1986) Biochemistry 25, 1371-1377 [Medline] [Order article via Infotrieve]
  6. Premont, R. T., Inglese, J. & Lefkowitz, R. J. (1995) FASEB J. 9, 175-182 [Abstract/Free Full Text]
  7. Hausdorff, W. P., Lohse, M. J., Bouvier, M., Liggett, S. B., Caron, M. G. & Lefkowitz, R. J. (1990) Symp. Soc. Exp. Biol. 44, 225-240 [Medline] [Order article via Infotrieve]
  8. Lohse, M. J., Lefkowitz, R. J., Caron, M. G. & Benovic, J. L. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 3011-3015 [Abstract]
  9. Benovic, J. L., Strasser, R. H., Caron, M. G. & Lefkowitz, R. J. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 2797-2801 [Abstract]
  10. Benovic, J. L., Kuhn, H., Weyand, I., Codina, J., Caron, M. G. & Lefkowitz, R. J. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 8879-8882 [Abstract]
  11. Clark, R. B., Kunkel, M. W., Friedman, J., Goka, T. J. & Johnson, J. A. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 1442-1446 [Abstract]
  12. Stickle, D. & Barber, R. (1989) Mol. Pharmacol. 36, 437-445 [Abstract]
  13. Clark, R. B., Friedman, J., Dixon, R. A. & Strader, C. D. (1989) Mol. Pharmacol. 36, 343-348 [Abstract]
  14. Shear, M., Insel, P. A., Melmon, K. L. & Coffino, P. (1976) J. Biol. Chem. 251, 7572-7576 [Abstract]
  15. Lefkowitz, R. J. (1993) Cell 74, 409-412 [Medline] [Order article via Infotrieve]
  16. Palczewski, K. & Benovic, J. L. (1991) Trends Biochem. Sci. 16, 387-391 [CrossRef][Medline] [Order article via Infotrieve]
  17. Lefkowitz, R. J., Inglese, J., Koch, W. J., Pitcher, J., Attramadal, H. & Caron, M. G. (1992) Cold Spring Harb. Symp. Quant. Biol. 57, 127-133 [Medline] [Order article via Infotrieve]
  18. Mahan, L. C., Koachman, A. M. & Insel, P. A. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 129-133 [Abstract]
  19. Alousi, A. A., Jasper, J. R., Insel, P. A. & Motulsky, H. J. (1991) FASEB J. 5, 2300-2303 [Abstract/Free Full Text]
  20. Leiber, D., Jasper, J. R., Alousi, A. A., Martin, J., Bernstein, D. & Insel, P. A. (1993) J. Biol. Chem. 268, 3833-3837 [Abstract/Free Full Text]
  21. Post, S. R., Hilal-Dandan, R., Urasawa, K., Brunton, L. L., and Insel, P. A. (1995) Biochem. J. 311, 75-80 [Medline] [Order article via Infotrieve]
  22. Insel, P. A., Bourne, H. R., Coffino, P. & Tomkins, G. M. (1975) Science 190, 896-898 [Medline] [Order article via Infotrieve]
  23. Hochman, J., Insel, P. A., Bourne, H. R., Coffino, P. & Tomkins, G. M. (1975) Proc. Natl. Acad. Sci. U. S. A. 72, 5051-5055 [Abstract]
  24. Mahan, L. C. & Insel, P. A. (1986) Mol. Pharmacol. 29, 16-22 [Abstract]
  25. Darfler, F. J., Mahan, L. C., Koachman, A. M. & Insel, P. A. (1982) J. Biol. Chem. 257, 11901-11907 [Free Full Text]
  26. Jasper, J. R., Michel, M. C. & Insel, P. A. (1990) Mol. Pharmacol. 37, 44-49 [Abstract]
  27. Dohlman, H. G., Caron, M. G. & Lefkowitz, R. J. (1987) Biochemistry 26, 2657-2664 [Medline] [Order article via Infotrieve]
  28. Premont, R. T., Jacobowitz, O. & Iyengar, R. (1992) Endocrinology 131, 2774-2784 [Abstract]
  29. Krupinski, J., Lehman, T. C., Frankenfield, C. D., Zwaagstra, J. C. & Watson, P. A. (1992) J. Biol. Chem. 267, 24858-24862 [Abstract/Free Full Text]
  30. Benovic, J. L., Pike, L. J., Cerione, R. A., Staniszewski, C., Yoshimasa, T., Codina, J., Caron, M. G. & Lefkowitz, R. J. (1985) J. Biol. Chem. 260, 7094-7101 [Abstract/Free Full Text]
  31. Pitcher, J., Lohse, M. J., Codina, J., Caron, M. G. & Lefkowitz, R. J. (1992) Biochemistry 31, 3193-3197 [Medline] [Order article via Infotrieve]
  32. Kunkel, M. W., Friedman, J., Shenolikar, S. & Clark, R. B. (1989) FASEB J. 3, 2067-2074 [Abstract/Free Full Text]
  33. Gilman, A. G. (1990) Adv. Second Messenger Phosphoprotein Res. 24, 51-57 [Medline] [Order article via Infotrieve]
  34. Iyengar, R. (1993) FASEB J. 7, 768-775 [Abstract/Free Full Text]
  35. Pieroni, J. P., Jacobowitz, O., Chen, J. & Iyengar, R. (1993) Curr. Opin. Neurobiol. 3, 345-351 [Medline] [Order article via Infotrieve]
  36. Tang, W. J. & Gilman, A. G. (1992) Cell 70, 869-872 [Medline] [Order article via Infotrieve]
  37. Taussig, R., Tang, W. J., Hepler, J. R. & Gilman, A. G. (1994) J. Biol. Chem. 269, 6093-6100 [Abstract/Free Full Text]
  38. Watson, P. A., Krupinski, J., Kempinski, A. M. & Frankenfield, C. D. (1994) J. Biol. Chem. 269, 28893-28898 [Abstract/Free Full Text]
  39. Taussig, R. & Gilman, A. G. (1995) J. Biol. Chem. 270, 1-4 [Free Full Text]
  40. Feldman, R. D. (1989) Mol. Pharmacol. 35, 304-310 [Abstract]
  41. Clark, R. B., Friedman, J., Johnson, J. A. & Kunkel, M. W. (1987) FASEB J. 1, 289-297 [Abstract/Free Full Text]
  42. Barber, R. (1988) Second Messengers Phosphoproteins 12, 59-71 [Medline] [Order article via Infotrieve]
  43. Sutkowski, E. M., Tang, W. J., Broome, C. W., Robbins, J. D. & Seamon, K. B. (1994) Biochemistry 33, 12852-12859 [Medline] [Order article via Infotrieve]
  44. Insel, P. A., Mahan, L. C., Motulsky, H. J., Stoolman, L. M. & Koachman, A. M. (1983) J. Biol. Chem. 258, 13597-13605 [Abstract/Free Full Text]
  45. Shih, M. & Malbon, C. C. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12193-12197 [Abstract/Free Full Text]
  46. Liggett, S. B., Bouvier, M., Hausdorff, W. P., O'Dowd, B., Caron, M. G. & Lefkowitz, R. J. (1989) Mol. Pharmacol. 36, 641-646 [Abstract]
  47. Hausdorff, W. P., Bouvier, M., O'Dowd, B. F., Irons, G. P., Caron, M. G. & Lefkowitz, R. J. (1989) J. Biol. Chem. 264, 12657-12665 [Abstract/Free Full Text]
  48. Ward, W. H., Timms, D. & Fersht, A. R. (1990) Trends Pharmacol. Sci. 11, 280-284 [Medline] [Order article via Infotrieve]
  49. Yuan, N., Friedman, J., Whaley, B. J. & Clark, R. B. (1994) J. Biol. Chem. 269, 23032-22038 [Abstract/Free Full Text]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.